Research programme: monoclonal antibody therapeutics - Aduro BioTech

Drug Profile

Research programme: monoclonal antibody therapeutics - Aduro BioTech

Alternative Names: ADU 1604

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen inhibitors; CD70 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 modulators; PDCD 1 protein inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 16 Nov 2017 Aduro Biotech announces intention to file an IND application with the US FDA for ADU 1604 for Cancer
  • 10 Nov 2017 Pharmacodynamics data from a preclinical trial in Cancer released by Aduro Biotech
  • 11 Oct 2017 9224302- ADU1604 added as a synonym
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top